MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571106 | Name: Remoxipride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Remoxipride is an antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia, particularly in the long term as a safer alternative to other anti-psychotic agents.

Chemical Structure

Remoxipride
Remoxipride
CAS#80125-14-0 (free base)

Theoretical Analysis

MedKoo Cat#: 571106

Name: Remoxipride

CAS#: 80125-14-0 (free base)

Chemical Formula: C16H23BrN2O3

Exact Mass: 370.0892

Molecular Weight: 371.28

Elemental Analysis: C, 51.76; H, 6.24; Br, 21.52; N, 7.55; O, 12.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
80125-14-0 (free base) 73220-03-8 (HCl) 117591-79-4 (HCl hydrate)
Synonym
Remoxipride
IUPAC/Chemical Name
Benzamide, 3-bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)-, (S)-
InChi Key
GUJRSXAPGDDABA-NSHDSACASA-N
InChi Code
InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
SMILES Code
O=C(NC[C@H]1N(CC)CCC1)C2=C(OC)C=CC(Br)=C2OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 371.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yisak W, Farde L, von Bahr C, Nilsson LB, Fredriksson G, Ogenstad S. Interaction study between remoxipride and biperiden. Psychopharmacology (Berl). 1993;111(1):27-32. PubMed PMID: 7870930. 2: Ma G, Friberg LE, Movin-Osswald G, Karlsson MO. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol. 2010 Dec;70(6):815-24. doi: 10.1111/j.1365-2125.2010.03758.x. PubMed PMID: 21175437; PubMed Central PMCID: PMC3014065. 3: Stevens J, Ploeger BA, van der Graaf PH, Danhof M, de Lange EC. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos. 2011 Dec;39(12):2275-82. doi: 10.1124/dmd.111.040782. Epub 2011 Sep 8. PubMed PMID: 21903866. 4: Widerlöv E, Andersson U, von Bahr C, Nilsson MI. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Psychopharmacology (Berl). 1991;103(1):46-9. PubMed PMID: 1672458. 5: Lapierre YD, Ancill R, Awad G, Bakish D, Beaudry P, Bloom D, Chandrasena R, Das M, Durand C, Elliott D, et al. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci. 1992 Oct;17(4):134-45. PubMed PMID: 1450186; PubMed Central PMCID: PMC1188438. 6: Wålinder J, Holm AC. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand Suppl. 1990;358:158-63. PubMed PMID: 1978477. 7: Lewander T. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Acta Psychiatr Scand Suppl. 1994;380:64-7. Review. PubMed PMID: 7914053. 8: Rammsayer T, Gallhofer B. Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles. Int Clin Psychopharmacol. 1995 Mar;10(1):31-7. PubMed PMID: 7622802. 9: Movin-Osswald G, Hammarlund-Udenaes M, Von Bahr C, Eneroth P, Walton-Bowen K. Influence of the dosing interval on prolactin release after remoxipride. Br J Clin Pharmacol. 1995 May;39(5):503-10. PubMed PMID: 7669486; PubMed Central PMCID: PMC1365057. 10: Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Möller K. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand Suppl. 1990;358:21-6. Review. PubMed PMID: 1978483. 11: Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatr Scand. 1993 Feb;87(2):114-7. PubMed PMID: 8447237. 12: Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P, et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand. 1994 Nov;90(5):358-65. PubMed PMID: 7872041. 13: Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74. PubMed PMID: 6149133. 14: Phanjoo AL, Link C. Remoxipride versus thioridazine in elderly psychotic patients. Acta Psychiatr Scand Suppl. 1990;358:181-5. PubMed PMID: 1978481. 15: den Boer JA, Westenberg HG. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. Psychopharmacol Bull. 1990;26(1):99-107. PubMed PMID: 1973547. 16: Yisak W, von Bahr C, Farde L, Grind M, Mattila M, Ogenstad S. Drug interaction studies with remoxipride. Acta Psychiatr Scand Suppl. 1990;358:58-62. PubMed PMID: 1978492. 17: Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther. 1995 Aug;274(2):921-7. PubMed PMID: 7636755. 18: Ahlenius S, Ericson E, Hillegaart V, Nilsson LB, Salmi P, Wijkström A. In vivo effects of remoxipride and aromatic ring metabolites in the rat. J Pharmacol Exp Ther. 1997 Dec;283(3):1356-66. PubMed PMID: 9400011. 19: King DJ, Blomqvist M, Cooper SJ, Doherty MM, Mitchell MJ, Montgomery RC. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology (Berl). 1992;107(2-3):175-9. PubMed PMID: 1352050. 20: van den Brink WJ, Wong YC, Gülave B, van der Graaf PH, de Lange EC. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. AAPS J. 2017 Jan;19(1):274-285. doi: 10.1208/s12248-016-0002-3. Epub 2016 Oct 26. PubMed PMID: 27785749.

View History

ND-378

ND-378

6-Alkynyl-fucose

6-Alkynyl-fucose

Fenpiverinium bromide

Fenpiverinium bromide

Caviphos

Caviphos

Demeclocycline calcium

Demeclocycline calcium

Fenoctimine sulfate

Fenoctimine sulfate